Nuveen
MRSN

Nuveen’s Mersana Therapeutics MRSN Stock Holding History

Nuveen’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,289
Closed -$79.9K – 3352
2025
Q1 		$79.9K Hold
9,289
– – ﹤0.01% 3234
2024
Q4 		$332K Buy
9,289
+3,241
+54% +$168K ﹤0.01% 3103
2024
Q3 		$286K Buy
6,048
+1,114
+23% +$49.2K ﹤0.01% 3154
2024
Q2 		$248K Hold
4,934
– – ﹤0.01% 3183
2024
Q1 		$553K Buy
4,934
+2,299
+87% +$229K ﹤0.01% 2944
2023
Q4 		$153K Hold
2,635
– – ﹤0.01% 3247
2023
Q3 		$83.7K Sell
2,635
-47,029
-95% -$2.24M ﹤0.01% 3139
2023
Q2 		$4.08M Buy
49,664
+5
+0% +$731 ﹤0.01% 2023
2023
Q1 		$5.1M Buy
49,659
+483
+1% +$67.8K ﹤0.01% 1876
2022
Q4 		$7.2M Sell
49,176
-1,589
-3% -$269K ﹤0.01% 1701
2022
Q3 		$8.58M Buy
50,765
+33,092
+187% +$5.38M ﹤0.01% 1575
2022
Q2 		$2.04M Buy
17,673
+5,695
+48% +$536K ﹤0.01% 2428
2022
Q1 		$1.2M Buy
11,978
+260
+2% +$30.4K ﹤0.01% 2743
2021
Q4 		$1.82M Buy
11,718
+670
+6% +$130K ﹤0.01% 2608
2021
Q3 		$2.6M Buy
11,048
+650
+6% +$190K ﹤0.01% 2547
2021
Q2 		$3.53M Buy
10,398
+701
+7% +$265K ﹤0.01% 2422
2021
Q1 		$3.92M Sell
9,697
-6,145
-39% -$2.98M ﹤0.01% 2286
2020
Q4 		$10.5M Buy
15,842
+1,075
+7% +$598K ﹤0.01% 1686
2020
Q3 		$6.87M Sell
14,767
-5,351
-27% -$2.7M ﹤0.01% 1747
2020
Q2 		$11.8M Buy
20,118
+12,387
+160% +$4.23M ﹤0.01% 1374
2020
Q1 		$1.13M Buy
7,731
+2,168
+39% +$379K ﹤0.01% 2467
2019
Q4 		$797K Buy
5,563
+1,251
+29% +$91.5K ﹤0.01% 2765
2019
Q3 		$171K Hold
4,312
– – ﹤0.01% 3135
2019
Q2 		$437K Buy
+4,312
New +$508K ﹤0.01% 3047

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nuveen's MRSN Position: Q2 2025 in Review

Nuveen sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 9,289 shares — an estimated $79.9K sold.

Nuveen first reported a position in MRSN in Q2 2019 and held it in 24 quarters. The position peaked at $11.8M in Q2 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Nuveen reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 9,289 Mersana Therapeutics shares in Q2 2025, an estimated $79.9K.
  • Nuveen first reported a position in Mersana Therapeutics in Q2 2019 and held it in 24 quarters.
  • Nuveen's Mersana Therapeutics position peaked at $11.8M in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.